Tositumomab - Wikipedia, the free encyclopedia
It sells in the U.S. under the trade name Bexxar. There is some evidence that it may cause a smaller decrease in platelet counts than ibritumomab tiuxetan does.
Human anti-mouse antibody - Wikipedia, the free encyclopedia
http://www.springerlink.com/content/9702202805311407/ ^ Bexxar.com http://www.bexxar.com/patients/bexxar_patientsmain.html ^ Klee GG.Human anti-mouse antibodies.
Tositumomab and Iodine I 131 Tositumomab
PRESCRIBING INFORMATION BEXXAR ® (Tositumomab and Iodine I 131 Tositumomab) WARNINGS Hypersensitivity Reactions, including Anaphylaxis: Serious hypersensitivity reactions ...
UMHS Press Release: Lymphoma drug effective over long term
June 4, 2007 . U-M study finds lymphoma drug effective over long term. 86% of patients treated with Bexxar survived after 8 years of follow up . ANN ARBOR, MI – Eight years after ...
Bexxar, Tositumomab Iodine - Chemotherapy Drugs, Chemo Side Effects
Bexxar is the trade name for Tositumomab. Tositumomab and Iodine I - 131 is another name for Tositumomab. Bexxar is a monoclonal antibody that is linked with a radioactive atom ...
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in ...
Bexxar [package insert]. Seattle, WA: Corixa Corp.; 2003. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated ...
Bexxar® Therapy
The Angeles Clinic and Research Institute, Inc. Center for Molecular Medicine 11818 Wilshire Boulevard Suite 200 Los Angeles California 90025 310.231.2140 office 310.231.2141 fax ...
Lymphoma Drug Bexxar Effective Over Long Term, Study Finds
ScienceDaily (June 7, 2007) — Eight years after being treated with a new drug for non-Hodgkin's lymphoma, 86 percent of patients were still alive and half had not had a relapse ...
Tositumomab - Wikipedia, the free encyclopedia
It sells in the U.S. under the trade name Bexxar. There is some evidence that it may cause a smaller decrease in platelet counts than ibritumomab tiuxetan does.
UMHS Press Release: New treatment rivals chemotherapy for lymphoma
More information about Bexxar: Health Minute: Newly approved therapy successfully targets cancer (Jan. 2004) http://www.med.umich.edu/opm/newspage/2004/bexxar.htm
